Roche's obinutuzumab significantly improves PFS in chronic lymphocytic leukemia The Pharma Letter ... with its investigational cancer drug obinutuzumab met its primary endpoint and an additional futility analysis suggested that it could show superiority compared to the company's currently marketed MabThera/Rituxan (rituximab) in first line chronic ... |
